A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...

This innovative software, CRISPRware, optimizes guide RNA design for genome editing, supporting research on genetic disorders ...

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery ...

Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.

The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe.

For people with Type 1 diabetes, developing hypoglycemia, or low blood sugar, is an ever-present threat. When glucose levels ...

Today, genomics is saving countless lives and even entire species, thanks in large part to a commitment to collaborative and ...

Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection ...

Ribosomally synthesized peptides as new antimicrobials Antimicrobial peptides are ribosomally synthesized antibiotic peptides produced by nearly all organisms, from bacteria to plants and animals.

ImmunoPrecise Antibodies Ltd., a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence- designed GLP-1 ...